Operator
Good day everyone and welcome to Ceronome's third quarter 2026 financial results and business update conference call. All participants are in a listen-only mode.
Following management's remarks, we will open the call for questions. This call is being recorded.
Ceronome issued its third quarter financial results on Friday. The release is available in the Investor Relations section of ceronome.com.
Joining us are Dr. Marc Hedrick, Ceronome's President and Chief Executive Officer; Dr.
Eric Daniels, Chief Operating Officer; Russell Bradley, President and General Manager of CNSide Diagnostics; and Andrew Simms, Chief Financial Officer. During today's call, we will make forward-looking statements, including statements about CNSide orders, payer coverage, and collections, our financial needs, and the timing and outcome of our Rayobic clinical and regulatory milestones.
These statements reflect our expectations as of today. Actual results may differ materially.
Please refer to Friday's release and our SEC filings, including the risk factors described there. We will undertake no obligation to update these statements except as required by law.
Dr. Hedrick, you may begin.
Dr. Marc Hedrick
Thank you Jamie. Good morning everyone, and thank you for joining us.
With me today are Russ Bradley, Eric Daniels, and Andrew Simms. On this morning's third quarter call, in addition to our usual quarterly reporting, we wanted to highlight data from our ReSPECT-LM trial, which we presented last Friday at the Society for Neuro-Oncology annual meeting in Philadelphia, as well as provide some interim commercial progress we've made with CNSide since our last call.
I'd first like to start off with a few general comments. I'm very pleased to announce that we've strengthened our leadership team with three important appointments.
First, Samantha Foelx has joined us as Vice President of Sales. We are on track with our commercial goals thus far with a small internal team and no dedicated sales staff.
Samantha is tasked with building our commercial team as we plan for strong growth in 2027. Second, Ronnie Andrews, a member of our board of directors, has agreed to join the management team as our Chief Business Officer.
Ronnie brings 35 years of experience across life sciences and diagnostics. He will focus on helping the company capitalize the business as well as expanding on our therapeutic and diagnostic partnerships.
Third, Dr. Eric Daniels has been promoted to Chief Operating Officer.
In this role, Eric will take on a broader operational mandate and support the increasingly integrated nature of our work across diagnostics, therapeutics, and advanced data analytics. As mentioned, our CNSide diagnostic business remains on track to meet the goals we set at the start of 2026.
We expect to exit 2026 at an annualized run rate of about 1,250 tests per year, and we've exceeded our 150 million total covered lives goal for our lead diagnostic, the tumor cell enumeration assay. We also remain on track to secure Medicare reimbursement in the first half of the year.
Russ will go into the details and walk through our plans for the rest of the year and give a preview of 2027. We are also on track to meet our Rayobic clinical development goals.
Most notably, we've closed enrollment in our ReSPECT-GBM Phase 2 trial and are making steady progress enrolling our ReSPECT-LM multi-dose optimization trial. Eric will discuss the ReSPECT-LM data presented at SNO last Friday.
We expect full top-line data from both trials, GBM and LM dose optimization, in mid-2027. Now I'd like to turn the call over to Eric to walk through the clinical update and take you through the data presented at SNO.
Eric?
Dr. Eric Daniels
Thank you Marc. Our lead asset, Rayobic, is a precision or targeted radiopharmaceutical for central nervous system cancers that we are advancing in the treatment of leptomeningeal metastases, recurrent glioblastoma, and pediatric malignant gliomas.
I'd like to take this quarterly opportunity to review our 2026 objectives and progress for Rayobic as follows. Objective number one is to define the optimal dose interval for Rayobic in the ReSPECT-LM Phase 2 trial, with an anticipated interim data readout in the second half of 2026.
This objective has been met, with interim data presented, as Marc mentioned, at the Society of Neuro-Oncology meeting this past weekend and press released this morning. I will take a moment to review the ongoing study, interim findings, and our plans ahead.
In this multi-dose study, we administer Rayobic, our liposomal targeted radiopharmaceutical, directly into the LM compartment through an implanted port or reservoir, thus bypassing the blood-brain barrier. In this dose optimization phase, we are evaluating various doses and various intervals between three repeat administrations of Rayobic, and measuring how much radiation reaches or is absorbed in the LM compartment over the course of the full treatment.
The interim multi-dose findings: at the 2026 Society of Neuro-Oncology annual meeting, we reported on the first 10 patients in this study, and here are the highlights. Patients were enrolled with a confirmed diagnosis of LM with a mix of primary tumor types, including three breast, one lung, four melanoma, and two ovarian.
Repeated dosing is working as designed. The 10 patients were treated across three cohorts, and dose escalation is continuing as planned.
To date, one patient received three 26.4 millicurie doses for a total of 79.2 millicuries administered. That is more than the 66 millicurie maximum feasible dose from our earlier Phase 1 study, with no observed dose-limiting toxicity.
Safety is clean so far. As I just mentioned, there have been no dose-limiting toxicities and no side effects that led to a patient to stop treatment.
The one Grade 3 treatment-related event was nausea, which is well known in intrathecal delivery, that resolved in five days. The one serious adverse event, shortness of breath, was judged unrelated to the drug.
Dosimetry is predictable from dose to dose. Within each dose, the radiation per millicurie varied by only 8% across repeat doses.
A single 13.2 millicurie dose delivers about 40 Gray to the fluid space around the brain, also consistent with our earlier study. Importantly, bone marrow exposure, which is the cause often of dose-limiting cytopenias, stays very low.
Early disease control signal is present, still descriptive. Only one of 10 patients had leptomeningeal progression through MRI documentation at 7.5 months.
Three patients died of their primary cancer, not the leptomeningeal disease, and six remain on study. Several patients' CSF tumor counts fell to zero and stayed there.
Overall, there was durable suppression of CSF tumor cell counts. What's next and what to watch?
Enrollment continues in the shorter interval and higher dose cohorts to define a recommended multiple dose regimen. Formal efficacy endpoints—response rate, progression-free survival, overall survival—are not yet assessable given we are still early in the trial timeline.
What is the path to approval for Rayobic in LM? Just as important as the initial data is the next steps.
At the end of our Phase 1 meeting in November 2025, the FDA aligned with our current ongoing dose optimization design for multiple doses of Rayobic. At the completion of the dose optimization study, we will meet with the agency with the body of safety, dosimetry, and preliminary efficacy data and agree on a randomized Phase 2 study.
We have alignment with the FDA this next study will include a dose randomization strategy, and we are contemplating an adaptive design to potentially include a control arm. Our aim is to emerge from the Phase 2 randomized study with a robust dataset capable of demonstrating substantial evidence of safety and effectiveness.
Candidate primary endpoints, subject to change, include neurologic function and overall survival. I'll now turn our attention to recurrent glioblastoma.
Our objective number two in 2026 was completing enrollment in the ReSPECT-GBM Phase 2 trial for glioblastoma and conducting an end of Phase 2 meeting with the FDA with the goal of aligning on a pivotal trial design, with data expected in Q4 2026. The objective of completing enrollment has been met this past quarter.
On October 29th, we announced we have closed Phase 2 enrollment after treating 32 patients at the recommended dose. The original plan was 34, yet after reviewing the statistical impact, we determined that closing at 32 would have minimal effect on the power of the planned analysis.
With ongoing data maturation and database cleaning, we expect to report top-line data from this study in mid-2027. Next steps following the data readout, including an end of Phase 2 meeting with the FDA, will be data-dependent.
Objective number three is to begin enrollment in the ReSPECT pediatric brain cancer Phase 1 trial. This objective has been met, as the trial is open and currently enrolling.
We look forward to keeping people updated on the trial progress in 2027. Objective number four is to complete commercial manufacturing scale-up for Rayobic.
This objective also remains in progress and on track to be completed by the end of the year. The recommendations from our Type C meeting with the FDA regarding purification, qualification, and impurity characterization are all on schedule to be completed by the end of the year, and method transfer is in process to a CDMO and the Q4 audit is planned by the end of the year.
We maintain that manufacturing scale-up and supply of Rayobic will readily support the early commercial activity. In addition to our stated objectives, we also announced preclinical data outlining a dual mechanism of action in aggressive epithelial ovarian cancer preclinical models.
The highlights include a dual MOA. Rayobic, in addition to its radiopharmaceutical properties, provides targeted local radiation that induces lethal DNA damage and apoptosis within 24 hours while simultaneously remodeling the tumor microenvironment.
Why is this important? For immune activation.
The therapy shifts immunologically cold tumors to hot ones by triggering innate immunity and reducing immunosuppressive signals like IL-10 and macrophage activity, both of which are elevated in tissue and ascites. What does this ultimately mean?
There is combination potential. Pairing Rayobic with an anti-PD-1 checkpoint blockade substantially boosted antitumor efficacy compared to single-agent approaches.
This dual mode of action opens the door to a whole host of combination potentials with Rayobic both within and even outside of the CNS. In summary, three of our four objectives for radiotherapeutics in 2026 are completed, and the fourth remains on track for completion by the end of the year.
We will continue to advance Rayobic, and we look forward to reading out top-line data for both the ongoing LM multi-dose and GBM studies in mid-2027. Thank you for your time, and I'll hand the call over to Russ for the CNSide update.
Russell Bradley
Thanks Eric. Since our September 30 update, CNSide has moved from submitting claims to recognizing revenue and receiving payments.
We recognized about $0.7 million of net diagnostic revenue in the third quarter, and commercial payers began paying our claims in October. Andrew will take you through the numbers.
October was our strongest month so far. We were up about 15% over our third quarter monthly average, bringing us to 512 tumor cell enumeration tests year-to-date.
Most of these, of course, are back-end loaded in the year, which is consistent with our expected ramp. That growth is coming from three separate drivers: new account activation and physician adoption, growth in patient monitoring, and an expanded test menu.
First, I'll go through the new accounts and physicians. 26 institutions and 45 providers are now ordering, up from 13 at the start of the year.
Growth is broadening outside our largest accounts. October test growth was 22% above the third quarter monthly average.
Behind that, we have a backlog we are clearing. Specifically, we have 34 more institutions in line to be onboarded.
Converting those will be the early focus of our growing commercial team. Second driver, patient monitoring.
Patient monitoring, or repeat testing of the same patient over time, is supported by the current National Comprehensive Cancer Network, or NCCN, guidelines for cancers of the central nervous system, and support this practice for patients on selected leptomeningeal treatment pathways. They recommend reassessing the CSF every four to eight weeks.
Every monitoring test comes from a new specimen and is a billable event from a patient already in our care. While still early into the launch timeline, nearly one in four patients has been tested more than once, and 23 have been tested four or more times.
Also, a growing number of our ordering institutions now use CNSide to monitor their patients. Each repeat order signals that physicians find the result useful in managing care.
Driver number three is expanding the test menu. On October 12th, we launched the CNSide CSF molecular profile for solid tumors and hematological malignancies, providing both RNA and DNA profiling from cerebrospinal fluid.
Tumor cell enumeration tells a physician whether tumor cells are present and how many. Molecular profile characterizes the alterations in that cancer, and so physicians can order either or both from the same patient draw.
The first molecular profiles were ordered and recorded in October, achieving a menu expansion goal we set in January of 2026. Behind the launch of the molecular profile last month, we are readying the launch of additional CSF cellular biomarkers to further characterize the tumor cells.
Market access: when we started the year, CNSide had contracted coverage for about 67 million lives, and we set a goal of reaching 150 million by year's end. Today we stand at approximately 190 million covered lives, or about 80% of U.S.
private payer coverage. Our recently announced agreement with Aetna is our first national agreement to include contracted rates for both tumor cell enumeration and molecular profiling.
A physician can now order both profiling tests from the same CSF sample in-network. On Medicare coverage, our proprietary billing code for tumor cell enumeration took effect on July 1st, and our enrollment is now complete.
Medicare reimbursement is a complex, multi-step process, and we are tracking for Medicare reimbursement in the first half of 2027. Now looking ahead, for the rest of this year, our priorities are converting onboarding accounts to first orders and growing the molecular profiling base alongside our proprietary tumor cell enumeration test, and, of course, building collections and claims that we submit.
In 2027, we will push on all three of these drivers. On adoption, we are building out our field sales team.
Their first priority is converting the 100 signed access agreements and the 34 onboarding accounts into active order centers and bringing multiple ordering physicians on board at each one. On monitoring, our goal is to make repeat CSF testing a routine part of how physicians follow their patients on treatment.
This is consistent with the NCCN guidelines. We will work with ordering physicians to build CNSide into their monitoring schedules, and we will continue generating the clinical evidence that supports monitoring, including the CSF data from our own ReSPECT-LM clinical trial for Rayobic.
On the expanding menu, our breast cancer cellular protein expression assays are now in validation testing, and we plan to launch them commercially in 2027. With tumor cell enumeration, molecular profiling, and protein expression available from a single CSF collection, oncologists will be able to confirm disease, characterize it, and follow it over time with one partner, and we'll be able to run more tests on each specimen.
Underpinning all three drivers, we expect to secure Medicare reimbursement in the first half of 2027, continue presenting clinical utility evidence to payers, and to build on our collection experience across the full CNSide menu. Put simply, adoption brings us more physicians and patients, monitoring brings more tests per patient, and the expanding menu brings us more tests per specimen.
Each one of these compounds on the others, and that is what we are building towards in 2027. CNSide also supports our therapeutic program.
In the ReSPECT-LM trial, we use it to follow CSF tumor cell counts in patients receiving Rayobic, which Eric just reviewed. With that, I'll turn it over to Andrew for the financial update.
Andrew Simms
Thanks, Russ. Let me start with CNSide, noting that there are three separate figures to keep in mind.
The first is gross billings. In Q3, we submitted claims for 222 tests, with gross charges of approximately $1.55 million.
That figure reflects list pricing. The second is net diagnostic revenue.
We recognized $0.7 million in the quarter. In determining net revenue, we estimate the amount we expect to receive after contractual adjustments and price concessions.
The third is cash. In October, we received approximately $0.1 million in cash collections.
Collections accelerate as our submitted billings ramp. As more claims are processed, we'll better define payer reimbursement behaviors and determine what, if any, adjustments we may need to make to revenue estimation.
These early and positive collections are an important first step in that process. On our September call, we discussed what an annualized gross billing run rate might look like as order volume increases and the menu expands.
That calculation used list prices and assumptions about which tests physicians would order, based in part on the 11,000 performed tests by CNSide's original developer. For modeling purposes, the additional inputs are the actual mix of tests ordered, the payer responsible for each claim, negotiated claim rates, and collection timing.
We now have some experience submitting claims, yet as I mentioned, we are still early in building the collection history needed to estimate those inputs more reliably. As I said in September, until we have payer experience and a collections history, we will use gross billings as the logical way to communicate business progress ahead of a revenue or cash number.
In terms of actual revenue guidance, we expect to have enough data points once we have two to three quarters of billing and collections in place to guide to a go-forward revenue estimate. Until then, we will focus on gross billings, and today we reaffirm our guidance: we expect to exit 2026 at an annualized gross billings run rate of approximately $10 million to $12.5 million.
Based on 2026 commercial patterns observed thus far, in 2027, we expect testing, billing, and collections to accelerate and materially offset CNSide's cash burn by the second half of 2027. If current trends continue and with a sales force, we could potentially start to see positive contribution late in 2027.
Turning to our consolidated results, total revenue for the quarter was $0.7 million, all from diagnostics. In the same quarter last year, revenue was $1.4 million, all from grants.
Cost of revenue this quarter was approximately $0.9 million. Research and development expense was $2.1 million, down primarily because CNSide moved from development into commercial operations, validation study costs from last year did not recur.
Selling, general, and administrative expense was $5.2 million, up from $3.4 million. The largest contributor to the year-over-year increase in SG&A was the expansion of our team, including the CNSide commercial build-out, which increased total compensation costs.
Recruiting costs also rose as we added staff. Facility rent and stock compensation also contributed.
Looking at the first nine months, we recognized $1.4 million in grant revenue, in addition to the $0.7 million in diagnostic revenue. Grant revenue was $3.8 million in the comparable period last year.
This helps explain why the year-over-year revenue comparison looks different from the progress we are seeing in diagnostics. Our operating loss was $7.5 million, compared to $4.5 million a year ago.
Net loss was $8.7 million, or $1.14 per share, compared with $4.4 million, or $1.03 per share, in last year's third quarter. This quarter also included $1.2 million in net financing expense.
We ended September with $4.9 million in cash, cash equivalents, and investments, compared with $8.6 million as of June 30. However, we raised just under $4 million in October and continue to have access to the $20 million royalty and financing facility we announced in September.
This combination, if fully accessed, extends runway into 2028. Marc, I'll turn it back to you.
Dr. Marc Hedrick
Thank you gentlemen. When we laid out our goals for the year, two key milestones we wanted to accomplish were giving patients more access to CNSide and completing enrollment in our recurrent glioblastoma study.
Both are achieved, and the team has made solid progress across the board. For CNSide, the next measures to watch are orders from the centers we brought on board and will bring on board through the year, cash collected on the claims we submit, as well as Medicare reimbursement.
For Rayobic, we expect top-line data from both glioblastoma Phase 2 and the LM multi-dose mid-year in 2027, and we plan to start a randomized Phase 2b study in LM in the second half of 2027. I just want to end by thanking the patients and the families who participate in our trials, and to the clinical teams who care for them.
Operator, Jamie, we're now ready for questions. In terms of questions, I'll take the initial question and then hand it off to any of our team as needed.
Operator
At this time, we will begin the question-and-answer session. To ask a question, you may press star and then one using a touch-tone telephone.
To withdraw your questions, you may press star and two. If you are using a speakerphone, we do ask that you please pick up the handset prior to pressing the keys to ensure the best sound quality.
Once again, that is star and then one to ask a question. We'll pause momentarily to assemble the roster.
Our first question today comes from Sean Lee from H.C. Wainwright.
Please go ahead with your question.
Sean Lee
Hey, good morning, guys, and congrats on the great results. I just have a couple questions on the LM data.
First, when do you expect to present the next update from this study? Will we be able to see things like the overall survival, the renal response, and also the quality of life, which, as I know, is very important for these patients?
Dr. Marc Hedrick
Hey Sean, thanks for the question. Eric, would you mind addressing that, please?
Dr. Eric Daniels
The next readout you can expect will be the top-line data from this study. We will enroll, targeting another 10 to 15 patients.
Having that enrollment plus maturation of the data, you can expect that in mid-2027. Yes, it will include by that time measures of progression-free survival and median overall survival, as well as neurological function and quality of life.
Sean Lee
Great to hear then, looking forward to this. My second question is on the correlation in LM progression between MRI and the CSF tumor cell via CNSide.
How well do those results correlate? Is the CNSide monitoring being able to, I guess, predict progression for these patients?
Dr. Marc Hedrick
Eric, please go ahead.
Dr. Eric Daniels
LM progression is measured along three traditional paths by criteria. Clinical suspicion, number one; number two, MRI or imaging; and number three, traditionally cytology or CSF evaluation.
They're all somewhat squishy at some level, predominantly MRI, and often times related to the amount of tumor burden. To answer your question, they often would correlate, but not entirely on a one-to-one or perfect correlation, which is why they have various degrees of sensitivity and specificity.
The CNSide test, or the tumor cell enumeration, has a higher sensitivity and specificity. When we look at the data at least from the first 10 patients, you do see a durable suppression.
I will refer you to an example on the poster that's available on our website, where you do see the one patient who did progress with an LM diagnosis, and you can see their tumor cell count starting to rise prior to the progression.
Sean Lee
Understood. That sounds very helpful.
My last question is on the comparison between the multi-dose and the single-dose. The one reported patient who received the three cumulative doses, the three 26 millicurie doses, seems to have a cumulative similar to what higher cohorts received in the single-dose study.
I was wondering, how do these compare in terms of both activity and toxicity?
Dr. Eric Daniels
That is really one of the big takeaways we would like people to see from these first 10 patients, which is the feasibility of doing fractionation. In other words, going back to the Phase 1 study, the maximum feasible dose was 66 millicuries, as I mentioned.
There was an additional cohort that had been administered 75 millicuries. Those were single-dose administrations.
In both of those cohorts, there was a dose-limiting toxicity related to the marrow. In this multi-dose study, the hypothesis was by fractionating that, you could actually deliver more millicuries, more absorbed radiation cumulatively, without the dose-limiting toxicity.
To be clear, we've had actually multiple patients receive three doses. However, we've just had one—and that's just been the natural progression of the enrollment—that's already received, numerically, the 79.2.
We've already exceeded the maximum amount of millicurie that was administered from the Phase 1, 79 greater than 75. There have been no dose-limiting toxicities.
When we look at the amount of radiation in the marrow, it is dramatically lower than it was for those two patients that had dose-limiting toxicities that I mentioned previously or referred to in the Phase 1. The bottom line is that we've broken the ceiling from Phase 1, and to date so far, feel very confident we could deliver ultimately more radiation, get and deliver more absorbed radiation, and avoid any of the dose-limiting toxicities that are known for not just Rayobic, but any radiopharmaceutical.
Sean Lee
Got it. That makes it much clearer.
Thanks again for taking my questions. I'll jump back in the queue.
Dr. Eric Daniels
Thank you.
Operator
Once again, if you would like to ask a question, please press star and one. To withdraw your questions, you may press star and two.
Our next question comes from Ed Woo from Ascendiant Capital. Please go ahead with your question.
Ed Woo
Congratulations on all the progress. As you build out your sales team for CNSide, have you identified how many sales people you think you may need, and how quickly will they be able to ramp up?
Dr. Marc Hedrick
Hey Ed, it's Marc. Thank you.
Russ Bradley, would you mind taking that question, please?
Russell Bradley
Sure Marc. Hi Ed.
We do have an initial tranche, I guess I'd call it, of salespeople. We've looked at where the bulk of the ordering activity is for CNSide and where the major centers are that treat these kinds of patients.
Initially, we're going to cover the U.S. with four salespeople and get them started—we're actually recruiting right now, we'll get them started and onboarded and trained.
Then I think we have some plans through the year based on continuing to grow and look at those territories to expand that commercial team to make sure that we're getting the efficiency and the effectiveness and coverage that we're looking for. In terms of how long it takes to ramp, the way we're profiling these professionals is that they have experience in precision oncology, they'll already come in with the experience to be able to work in the role as we've defined it.
We have a pretty extensive training program ready to go to get them up and going. We think that they'll be effective within 90 days in the space, but they'll be out there introducing themselves to accounts that we have and some of the onboarded accounts that I was referring to in my remarks.
I think it's an initial start. We've also looking to hire the supporting team, because obviously the people in the field need support as well, and those interviews and that recruiting is well underway.
It's a plan right now to deliver a full package of commercial effectiveness in Q1. I'm expecting in Q1 that we'll have feet on the ground already growing our business and impacting the number of accounts that we can bring on board.
Hopefully that answers your question.
Ed Woo
Yes, Russ. Thank you very much.
My last question is on the lab capacity. Is there any issues potentially as you ramp up your test in terms of how much test you can process?
Russell Bradley
Yes, Marc, do you want me to take that?
Dr. Marc Hedrick
Please.
Russell Bradley
Yeah. Ed, we recently moved our lab for that very purpose of expanding capacity.
In September, we moved to our new facility at Leagreen, so that we could expand capacity, and we've got a critical eye on making sure that we're able to grow our test volume. Right now, our capacity is significantly in advance of our current volume.
In fact, the capacity in the current site, and our future expansion plans, is out through probably 10 years. I don't believe capacity constraints are going to stop our growth.
We've had a very deliberate approach to making sure that we've got the capacity to meet the demand that we're seeing, and for years into the future. Happy to update on that, but at the moment, we don't foresee any capacity issues.
Ed Woo
Great. Thank you and I wish you guys good luck.
Thank you.
Russell Bradley
Thank you, Ed.
Operator
At this time, we do have a written-in question, and I'd like to turn the floor over to Andrew for that question.
Andrew Simms
Thanks, Jamie. The question is, can management outline the path to a positive contribution from the CNSide diagnostic, and outline expected timeline to achieve that?
Marc, if it's okay, I'll take that?
Dr. Marc Hedrick
Sure, go ahead. Thanks Andrew.
Andrew Simms
As I laid out in my prepared comments, we guided to exiting the year at gross billing of $10 to $12.5 million of gross revenue. For simplification and to provide kind of a straightforward answer, we're seeing initial collections of approximately 50% of that number, and we expect that to grow over time.
As we look ahead into 2027 with the growth of the sales force, continued growth, as Russ laid out, both in terms of core TCE sales, together with expanding menu of items for the overall sample, we expect that gross billing revenue number to double in 2027. To put it in the range of $20 to $25 million of gross revenue by the end of 2027.
The overall burn for CNSide currently is about $10 million a year. You can see that on pretty straightforward math that kind of exiting forecast or revenue number at the end of 2027 equates to, or more than equates to, the overall cash burn that we project in 2027.
We expect to hit that positive contribution at that higher revenue number that I just outlined. On that, Marc, I'll turn it back over to you.
Dr. Marc Hedrick
Great. Thank you.
Just to follow on from that, I think at this point, we're not ready to forecast and provide guidance for 2027. I think we'd like to have another month or two of operational information that we can refine our forecast, but think you have enough information to see where the business is going.
I think I'd just go ahead and conclude the day. Thank you for the questions.
Thank you to everyone that's joining us today online for your interest in Ceronome, and we'll continue to update you closely on progress along the way for the remainder of 2026 and into 2027. Thank you.
Operator
With that, we'll be concluding today's conference call and presentation. We do thank you for joining.
You may now disconnect your lines.